.Pharmacolibrary.Drugs.ATC.N.N06AX18

Information

Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) used for the treatment of major depressive disorder. It is approved in several countries (e.g., some countries in Europe, but not the United States) for adult patients with depression.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after oral administration.

References

1. Fleishaker, JC (2000). Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clinical pharmacokinetics 39(6) 413–427. DOI:10.2165/00003088-200039060-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11192474

2. Hendershot, PE, et al., & Poland, RE (2001). Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. Psychopharmacology 155(2) 148–153. DOI:10.1007/s002130100696 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11401003

3. Kasper, S, et al., & Hilger, E (2000). Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert opinion on pharmacotherapy 1(4) 771–782. DOI:10.1517/14656566.1.4.771 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11249515

Revisions

• 06/2025 initial generated model